Home » Diabetes » Lupin receives mn from AbbVie to initiate novel MALT1 inhibitor program clinical trial, ET HealthWorld

Lupin receives $25 mn from AbbVie to initiate novel MALT1 inhibitor program clinical trial, ET HealthWorld

Share Now :

Facebook
Twitter
WhatsApp
Telegram

Mumbai: Global pharma major Lupin Limited today announced that it has received USD 25 million from AbbVie for initiation of Phase 1 clinical studies successfully for its novel MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program aimed towards treatment across a range of hematological cancers.

Lupin had earlier received USD 30 million from AbbVie for achievement of other milestones in the program.

Lupin and AbbVie inked the licensing, development, and commercialization agreement in 2018 for this novel oncology drug to treat Hematological Cancers. Lupin’s MALT1 inhibitor developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination.

“This achievement is further validation of our ability to successfully develop novel treatments for unmet needs. We look forward to continued successful development of this important treatment for patients with difficult-to-treat cancers,” said Nilesh Gupta, Managing Director, Lupin.

  • Published On Jun 29, 2023 at 06:21 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App

Source link

madhuprayas
Author: madhuprayas

Leave a Comment

Related Post